 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C13H17NO |
| Molar mass | 203.28 g/mol (freebase) 239.78 g/mol (hydrochloride) g·mol−1 |
| 3D model (JSmol) | |
| |
| |
5-MBPB (also known as5-MPBP and5-MABB) is anamphetamine andphenylisobutylaminederivative which isstructurally related toMDMA and has been sold as adesigner drug. It can be described as thebenzofuran-5-ylanalogue ofMBDB or the butanaminehomologue of5-MAPB, and is also astructural isomer of5-EAPB and6-EAPB. Anecdotal reports suggest this compound has been sold as a designer drug in various European countries since early 2015, but the first definitive identification was made in December 2015 by a forensic laboratory inSlovenia.[1]
5-MBPB is similar in structure to compounds such as5-APB which are claimed to be agonists of the5-HT2C receptor.[2]
5-MBPB (5-MABB) has been found to act as apotentserotonin–norepinephrine–dopamine releasing agent (SNDRA), with preference for induction ofserotonin release overnorepinephrine anddopamine release, and fully substitutes for MDMA in animaldrug discrimination tests.[3] Unlike5-MAPB, it is a relatively weakserotonin5-HT1B receptoragonist.[4]
